Home > Resources > Videos > SiriusDecisions B-to-B Fundamentals with Elisabeth Medaris

SiriusDecisions B-to-B Fundamentals with Elisabeth Medaris

At SiriusDecisions, we’ve created a b-to-b fundamentals course to help you build a strong foundation of knowledge and develop meaningful, ongoing relationships with customers.

Spotlight

Tango Therapeutics

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

OTHER VIDEOS

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now
MORE VIDEOS

Spotlight

Tango Therapeutics

Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.

Events